OBJECTIVES: To develop a prognostic nomogram to predict the freedom from recurrence for patients treated with permanent prostate brachytherapy for localized prostate cancer. METHODS: We performed a retrospective analysis of 920 patients treated with permanent prostate brachytherapy between 1992 and 2000. The clinical parameters included clinical stage, biopsy Gleason sum, pretreatment prostate-specific antigen (PSA) value, and administration of external beam radiation. Patients who received neoadjuvant androgen deprivation therapy were excluded. Failure was defined as any post-treatment administration of androgen deprivation, clinical relapse, or biochemical failure, defined as three PSA rises. Patients with fewer than three PSA rises were censored at the time of the first PSA rise. Data from two outside institutions served as validation. RESULTS: A nomogram that predicts the probability of remaining free from biochemical recurrence for 5 years after brachytherapy without adjuvant hormonal therapy was developed using Cox proportional hazards regression analysis. External validation revealed a concordance index of 0.61 to 0.64, and calibration of the nomogram suggested confidence limits of +5% to -30%. CONCLUSIONS: The pretreatment nomogram we developed may be useful to physicians and patients in estimating the probability of successful treatment 5 years after brachytherapy for clinically localized prostate cancer.
OBJECTIVES: To develop a prognostic nomogram to predict the freedom from recurrence for patients treated with permanent prostate brachytherapy for localized prostate cancer. METHODS: We performed a retrospective analysis of 920 patients treated with permanent prostate brachytherapy between 1992 and 2000. The clinical parameters included clinical stage, biopsy Gleason sum, pretreatment prostate-specific antigen (PSA) value, and administration of external beam radiation. Patients who received neoadjuvant androgen deprivation therapy were excluded. Failure was defined as any post-treatment administration of androgen deprivation, clinical relapse, or biochemical failure, defined as three PSA rises. Patients with fewer than three PSA rises were censored at the time of the first PSA rise. Data from two outside institutions served as validation. RESULTS: A nomogram that predicts the probability of remaining free from biochemical recurrence for 5 years after brachytherapy without adjuvant hormonal therapy was developed using Cox proportional hazards regression analysis. External validation revealed a concordance index of 0.61 to 0.64, and calibration of the nomogram suggested confidence limits of +5% to -30%. CONCLUSIONS: The pretreatment nomogram we developed may be useful to physicians and patients in estimating the probability of successful treatment 5 years after brachytherapy for clinically localized prostate cancer.
Authors: Dwight E Heron; Karen D Godette; Ray A Wynn; V Elayne Arterbery; Oscar A Streeter; Mack Roach; Joseph R Simpson; Melissa Blough; Charles R Thomas Journal: J Natl Med Assoc Date: 2003-01 Impact factor: 1.798
Authors: Matthew S Katz; Jason A Efstathiou; Anthony V D'Amico; Michael W Kattan; Martin G Sanda; Paul L Nguyen; Matthew R Smith; Peter R Carroll; Anthony L Zietman Journal: BJU Int Date: 2010-03-15 Impact factor: 5.588
Authors: Giovanni Lughezzani; Alberto Briganti; Pierre I Karakiewicz; Michael W Kattan; Francesco Montorsi; Shahrokh F Shariat; Andrew J Vickers Journal: Eur Urol Date: 2010-08-06 Impact factor: 20.096
Authors: Rainer Kuefer; Kathleen C Day; Celina G Kleer; Michael S Sabel; Matthias D Hofer; Sooryanarayana Varambally; Christoph S Zorn; Arul M Chinnaiyan; Mark A Rubin; Mark L Day Journal: Neoplasia Date: 2006-04 Impact factor: 5.715
Authors: Andrew J Stephenson; Alex Smith; Michael W Kattan; Jaya Satagopan; Victor E Reuter; Peter T Scardino; William L Gerald Journal: Cancer Date: 2005-07-15 Impact factor: 6.860
Authors: Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino Journal: Future Oncol Date: 2009-12 Impact factor: 3.404